Both body creams and lotions hydrate skin, but they have a few key differences. The main is consistency. Here’s how to tell ...

and mupirocin ointment. Patch testing with the North American Contact Dermatitis Group (NACDG) standard tray, corticosteroids, vehicles, preservatives, flavorings, corticosteroids, cosmetics ...

Atopic dermatitis is the most common type of eczema ... Be sure to check that the cream and/or lotion has the National Eczema Association’s Seal of Approval and doesn’t have any ingredients ...

If you can already feel the moisture-sucking wind of the winter ahead, now is the time to drop this all-purpose salve into ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

A 67-year-old patient with a personal history of systemic scleroderma and chronic renal failure and who had been in hemodialysis since 2004 presented with an itchy, erythematous, and desquamative ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.